Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 7/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18516817 | 0.89 | ALDH1A1 (0.46) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL39919 | 0.86 | ALDH1A1 (0.59) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL10175678 | 0.85 | ALDH1A1 (0.43) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL27055855 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL27055890 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL13739822 | 0.81 | ALDH1A1 (0.43) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL10175669 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL27055876 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL27055872 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TP53HIF1ACYP3A4MAPK1 | |
| SCHEMBL27055862 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TP53HIF1ACYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663671-B2 | Curable composition for imprints and method of storing the same | FUJIFILM CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| US-8933144-B2 | Curable composition for imprint, pattern-forming method and pattern | FUJIFILM CORPORATION (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8877828-B2 | Method for producing curable composition for imprints | FUJIFILM CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8851624-B2 | Maintenance liquid | FUJIFILM CORPORATION (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20140255662-A1 | CURABLE COMPOSITION FOR IMPRINT, PATTERN-FORMING METHOD AND PATTERN | FUJIFILM CORPORATION (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8820541-B2 | Method for producing curable composition for imprints | FUJIFILM CORPORATION (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20140227493-A1 | CURABLE COMPOSITION FOR IMPRINTS AND METHOD OF STORING THE SAME | FUJIFILM CORPORATION (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8783823-B2 | Maintenance liquid | FUJIFILM CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140048754-A1 | MAINTENANCE LIQUID | FUJIFILM CORPORATION (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20120207943-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION FOR IMPRINTS | FUJIFILM CORPORATION (JP) | 2012-08-16 | — | — | US | disclosed |
| US-20120076948-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION FOR IMPRINTS | FUJIFILM CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120004385-A1 | MAINTENANCE LIQUID | FUJIFILM CORPORATION (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004385-A1 | MAINTENANCE LIQUID | EED, PRDM9, DOT1L | ALDH1A1 1272/4885TP53 1201/4885HIF1A 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.